{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:56:15Z","timestamp":1792803375411,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2025.11.001","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:28:20Z","timestamp":1763648900000},"page":"208-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5013-7617","authenticated-orcid":false,"given":"Clara","family":"Cerrato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.11.001_b0005","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2274123","article-title":"Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article","volume":"24","author":"Dong","year":"2023","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.euo.2025.11.001_b0010","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc4308","article-title":"A mathematical model of ctDNA shedding predicts tumor detection size","volume":"6","author":"Avanzini","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.euo.2025.11.001_b0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.euo.2025.05.019","article-title":"Real-world experience with a commercial circulating tumor DNA assay in non\u2013muscle-invasive bladder cancer","volume":"8","author":"Wang","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.001_b0020","doi-asserted-by":"crossref","unstructured":"Powles T, Kann AG, Castellano D. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. In press. https:\/\/doi.org\/10.1056\/NEJMoa2511885.","DOI":"10.1056\/NEJMoa2511885"},{"key":"10.1016\/j.euo.2025.11.001_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.001_b0030","doi-asserted-by":"crossref","unstructured":"Roupret M, Bertaut A, Pignot G, et al. ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC). Ann Oncol. In press. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017.","DOI":"10.1016\/j.annonc.2026.01.017"},{"key":"10.1016\/j.euo.2025.11.001_b0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.11.001_b0040","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.21037\/tau-24-7","article-title":"Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer","volume":"13","author":"Lindskrog","year":"2024","journal-title":"Transl Androl Urol"},{"issue":"16","key":"10.1016\/j.euo.2025.11.001_b0045","article-title":"164P Early evaluation of effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer","volume":"21","author":"Kramer","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.euo.2025.11.001_b0050","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:34:20Z","timestamp":1777602860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931125002895"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.11.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}